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Abstract: CLINICAL CHARACTERISTICS: McLeod neuroacanthocytosis syndrome (designated as
MLS throughout this review) is a multisystem disorder with central nervous system (CNS), neuromuscu-
lar, cardiovascular, and hematologic manifestations in males. CNS manifestations are a neurodegenera-
tive basal ganglia disease including (1) movement disorders, (2) cognitive alterations, and (3) psychiatric
symptoms. Neuromuscular manifestations include a (mostly subclinical) sensorimotor axonopathy and
muscle weakness or atrophy of different degrees. Cardiac manifestations include dilated cardiomyopa-
thy, atrial fibrillation, and tachyarrhythmia. Hematologically, MLS is defined as a specific blood group
phenotype (named after the first proband, Hugh McLeod) that results from absent expression of the
Kx erythrocyte antigen and weakened expression of Kell blood group antigens. The hematologic man-
ifestations are red blood cell acanthocytosis and compensated hemolysis. Allo-antibodies in the Kell
and Kx blood group system can cause strong reactions to transfusions of incompatible blood and severe
anemia in affected male newborns of Kell-negative mothers. Females heterozygous for XK pathogenic
variants have mosaicism for the Kell and Kx blood group antigens but usually lack CNS and neuromus-
cular manifestations; however, some heterozygous females may develop clinical manifestations including
chorea or late-onset cognitive decline. DIAGNOSIS/TESTING: The diagnosis of MLS is established in a
male proband with suggestive clinical, laboratory, and neuroimaging studies; a family history consistent
with X-linked inheritance; and identification on molecular genetic testing of either a hemizygous XK
pathogenic variant (90% of affected males) or a hemizygous deletion of Xp21.1 involving XK (10% of
affected males). MANAGEMENT: Treatment of manifestations: Dopamine antagonists (e.g., tiapride,
clozapine, quetiapine) and the dopamine depletory (tetrabenazine) to ameliorate chorea; treatment of
psychiatric problems, cardiac abnormalities, and seizures is based on the clinical findings; long-term and
continuous multidisciplinary psychosocial support is needed for affected individuals and their families.
Agents/circumstances to avoid: Blood transfusions with Kx antigens should be avoided in males with
MLS. Kx-negative blood or, if possible, banked autologous blood should be used. Evaluation of rela-
tives at risk: It is appropriate to clarify the genetic status of apparently asymptomatic at-risk relatives
of any age in order to identify as early as possible those who would benefit from: (1) detailed blood
compatibility information to prevent transfusion of Kx+ homologous blood products, and (2) possible
prophylactic cryopreservation of autologous blood for use in future transfusions. Surveillance: Holter
ECG and echocardiography every two to three years in those without known cardiac complications;
consider placement of prophylactic cardiac pacemaker; monitor for seizures; monitor serum CK con-
centrations for evidence of rhabdomyolysis if excessive movement disorders are present or if neuroleptic
medications are being used. GENETIC COUNSELING: MLS is inherited in an X-linked manner. If the
mother of an affected male is heterozygous, the chance of transmitting the XK pathogenic variant in each
pregnancy is 50%. Males who inherit the XK variant will be affected; females who inherit the XK variant
will be heterozygous and will usually not be affected. Affected males pass the XK pathogenic variant to
all of their daughters and none of their sons. Once the XK pathogenic variant has been identified in an
affected family member, carrier testing for at-risk females, prenatal testing for a pregnancy at increased
risk, and preimplantation genetic diagnosis are possible.
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Summary
Clinical characteristics
McLeod neuroacanthocytosis syndrome (designated as MLS throughout this review) is a multisystem disorder 
with central nervous system (CNS), neuromuscular, cardiovascular, and hematologic manifestations in males. 
CNS manifestations are a neurodegenerative basal ganglia disease including (1) movement disorders, (2) 
cognitive alterations, and (3) psychiatric symptoms. Neuromuscular manifestations include a (mostly 
subclinical) sensorimotor axonopathy and muscle weakness or atrophy of different degrees. Cardiac 
manifestations include dilated cardiomyopathy, atrial fibrillation, and tachyarrhythmia. Hematologically, MLS is 
defined as a specific blood group phenotype (named after the first proband, Hugh McLeod) that results from 
absent expression of the Kx erythrocyte antigen and weakened expression of Kell blood group antigens. The 
hematologic manifestations are red blood cell acanthocytosis and compensated hemolysis. Allo-antibodies in the 
Kell and Kx blood group system can cause strong reactions to transfusions of incompatible blood and severe 
anemia in affected male newborns of Kell-negative mothers. Females heterozygous for XK pathogenic variants 
have mosaicism for the Kell and Kx blood group antigens but usually lack CNS and neuromuscular 
manifestations; however, some heterozygous females may develop clinical manifestations including chorea or 
late-onset cognitive decline.
Diagnosis/testing
The diagnosis of MLS is established in a male proband with suggestive clinical, laboratory, and neuroimaging 
studies; a family history consistent with X-linked inheritance; and identification on molecular genetic testing of 
either a hemizygous XK pathogenic variant (90% of affected males) or a hemizygous deletion of Xp21.1 
involving XK (10% of affected males).
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Management
Treatment of manifestations: Dopamine antagonists (e.g., tiapride, clozapine, quetiapine) and the dopamine 
depletory (tetrabenazine) to ameliorate chorea; treatment of psychiatric problems, cardiac abnormalities, and 
seizures is based on the clinical findings; long-term and continuous multidisciplinary psychosocial support is 
needed for affected individuals and their families.
Agents/circumstances to avoid: Blood transfusions with Kx antigens should be avoided in males with MLS. Kx-
negative blood or, if possible, banked autologous blood should be used.
Evaluation of relatives at risk: It is appropriate to clarify the genetic status of apparently asymptomatic at-risk 
relatives of any age in order to identify as early as possible those who would benefit from: (1) detailed blood 
compatibility information to prevent transfusion of Kx+ homologous blood products, and (2) possible 
prophylactic cryopreservation of autologous blood for use in future transfusions.
Surveillance: Holter ECG and echocardiography every two to three years in those without known cardiac 
complications; consider placement of prophylactic cardiac pacemaker; monitor for seizures; monitor serum CK 
concentrations for evidence of rhabdomyolysis if excessive movement disorders are present or if neuroleptic 
medications are being used.
Genetic counseling
MLS is inherited in an X-linked manner. If the mother of an affected male is heterozygous, the chance of 
transmitting the XK pathogenic variant in each pregnancy is 50%. Males who inherit the XK variant will be 
affected; females who inherit the XK variant will be heterozygous and will usually not be affected. Affected males 
pass the XK pathogenic variant to all of their daughters and none of their sons. Once the XK pathogenic variant 
has been identified in an affected family member, carrier testing for at-risk females, prenatal testing for a 
pregnancy at increased risk, and preimplantation genetic diagnosis are possible.
Diagnosis
Suggestive Findings
The diagnosis of McLeod neuroacanthocytosis syndrome (MLS) should be suspected/considered in an 
individual with the following clinical and laboratory findings and family history.
Clinical Findings
CNS manifestations
• Progressive chorea syndrome similar to that seen in Huntington disease including the clinical triad of 
movement disorder, cognitive alterations, and psychiatric manifestations
• Seizures, mostly generalized
Neuromuscular manifestations (often subclinical or mild)
• Sensorimotor axonopathy
• Neurogenic muscle atrophy, including unexplained elevation of creatine phosphokinase
• Myopathy
Cardiomyopathy
• Echocardiography may demonstrate congestive cardiomyopathy or dilated cardiomyopathy [Mohiddin & 
Fananapazzir 2004].
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• Electrocardiography (ECG) may demonstrate atrial fibrillation or tachyarrhythmia [Mohiddin & 
Fananapazzir 2004].
Family history consistent with X-linked inheritance
Laboratory/Electrophysiologic Findings
McLeod blood group phenotype
• In affected males the diagnosis of the McLeod blood group phenotype is based on the 
immunohematologic determination of absent expression of the Kx erythrocyte antigen and reduced 
expression of the Kell blood group antigens using human anti-Kx and monoclonal anti-Kell antibodies, 
respectively [Jung et al 2007, Roulis et al 2018]. Serologically absent Kx erythrocyte antigen and 
serologically weakened or absent Kell antigens are pathognomonic for the McLeod blood group 
phenotype.
McLeod blood group phenotype is established by showing negativity for Kx erythrocyte antigen and 
weakened or absent expression of Kell antigens, thus differentiating the phenotype from individuals with 
KEL-null (K0) phenotype, which is characterized by strong expression of Kx. Expression of Kx / Kell 
protein complex on red blood cell membrane can also be evaluated by flow cytometry.
• In heterozygous females mixed red blood cell populations may be identified with flow cytometric analysis 
of Kx and Kell RBC antigens on red blood cell membrane [Jung et al 2007, Roulis et al 2018].
Red blood cell studies
• RBC acanthocytosis is found in virtually all males with MLS. Accurate determination of RBC 
acanthocytosis is challenging. The best procedure requires diluting whole blood samples 1:1 with 
heparinized saline followed by incubation for 60 minutes at room temperature; wet cell monolayers are 
then prepared for phase-contrast microscopy. When all RBCs with spicules (corresponding to type AI/AII 
acanthocytes and echinocytes) are counted, normal controls show less than 6.3% acanthocytes/
echinocytes [Storch et al 2005]. Acanthocyte count in MLS may vary considerably but usually ranges 
between 8% and 30%. Repeat testing may be required, as the findings of acanthocyte determinations may 
fluctuate over time. Proven presence of acanthocytes, however, is not a necessary precondition to make the 
diagnosis of the McLeod neuroacanthocytosis syndrome. Note: No data regarding the age at which 
acanthocytosis develops are available.
Confirmation of erythrocyte morphology by scanning electron microscopy (if available) may be helpful.
Compensated hemolysis (i.e., hemolysis without anemia) is found in virtually all males with MLS. The following 
can be used to evaluate for hemolysis:
• Assessment for allo-antibodies against high-frequency antigens (anti-public antibodies) such as anti-Kx, 
anti-K20, and anti-Km antibodies. While these anti-public antibodies do not contribute to the auto-
hemolysis in MLS, they need to be considered in homologous transfusion.
• Exclusion of autoimmune hemolytic anemia by negative direct antiglobulin test
• Investigation for biochemical markers of hemolysis (LDH, haptoglobin, bilirubin, reticulocytes) and 
muscle disorder (CPK, CPK-MB)
Neuromuscular studies
• Muscle enzymes. All males with MLS examined to date have had elevated serum creatine phosphokinase 
(CK) concentrations reaching values up to 4,000 U/L [Danek et al 2001a, Jung et al 2001a].
• Electromyography may demonstrate neurogenic and myopathic changes [Danek et al 2001a].
• Nerve conduction studies may demonstrate axonal damage of variable degree [Danek et al 2001a].
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• Muscle computed tomography (CT) may reveal a selective pattern of fatty degeneration of lower-leg 
muscles preferentially affecting the vastus lateralis, biceps femoris, and adductor magnus muscles, and 
sparing the gracilis, semitendinosus, and lateral head of the gastrocnemius muscle [Ishikawa et al 2000].
Central Nervous System Studies
Neuroimaging
• In affected males, CT and magnetic resonance imaging (MRI) of the brain may demonstrate atrophy of 
the caudate nucleus and putamen of variable degree [Danek et al 2001a, Jung et al 2001a]. Basal ganglia 
volumes are inversely correlated with disease duration [Jung et al 2001a]. A follow-up study of three 
individuals with MLS over seven years using an automated subcortical segmentation procedure 
demonstrated decreasing caudate volumes [Valko et al 2010].
• In two males with MLS, brain MRI demonstrated extended T2-weighted hyperintense white matter 
alterations [Danek et al 2001a, Nicholl et al 2004].
• In asymptomatic heterozygous females, and early in the disease course in affected males, neuroimaging 
findings may be normal [Jung et al 2001a, Jung et al 2003].
Establishing the Diagnosis
Male proband. The diagnosis of McLeod neuroacanthocytosis syndrome is established in a male proband with 
suggestive clinical and laboratory findings, neuroimaging studies, and family history, as well as one of the 
following identified on molecular genetic testing (see Table 1):
• A hemizygous pathogenic variant involving XK (~90% of affected individuals) [Dotti et al 2000, Danek et 
al 2001a, Jung et al 2001b, Jung et al 2003]
• A hemizygous deletion of Xp21.1 involving XK (10% of affected individuals) [Kawakami et al 1999, El 
Nemer et al 2000, Danek et al 2001a, Wendel et al 2004]
Note: Deletions involving XK vary in size from intragenic to larger multigene deletions. Failure to generate 
XK sequence in a male proband is consistent with a deletion; however, other techniques are needed to 
define the breakpoints of the deletion (see Table 1).
Female proband. The diagnosis of McLeod neuroacanthocytosis syndrome is usually established in a female 
proband with one of the following: (1) detection by flow cytometry of two populations of RBC, one with normal 
expression of Kell antigens and one with reduced expression, or (2) detection of a heterozygous pathogenic 
variant in XK by molecular genetic testing.
Note: Based on published cases, heterozygous females do not have RBC acanthocytosis or elevated CK serum 
levels.
Molecular genetic testing approaches can include a combination of gene-targeted testing (single-gene testing, 
multigene panel) and comprehensive genomic testing (chromosomal microarray analysis, exome sequencing, 
exome array, genome sequencing). Gene-targeted testing requires that the clinician determine which gene(s) are 
likely involved, whereas genomic testing does not.
There are three options for establishing the diagnosis of McLeod neuroacanthocytosis syndrome:
• Option 1. Determination of the McLeod blood group phenotype followed by CMA for individuals with 
findings suggestive of a contiguous-gene deletion
• Option 2. Determination of the McLeod blood group phenotype followed by single-gene testing for those 
in whom McLeod blood group phenotyping supports the diagnosis
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• Option 3. Multigene panel or comprehensive genomic testing for symptomatic individuals in whom the 
diagnosis of McLeod neuroacanthocytosis syndrome has not been considered
Option 1
(Determination of the McLeod blood group phenotype followed by CMA for individuals with findings 
suggestive of a contiguous-gene deletion)
Chromosomal microarray analysis (CMA). For individuals with suggestive clinical features of McLeod 
neuroacanthocytosis syndrome and one or more of the disorders observed in contiguous-gene deletions that 
include XK, CMA should be performed first to detect large deletions that cannot be detected by sequence 
analysis or gene-targeted deletion/duplication analysis. These other disorders and their causative genes include 
Duchenne muscular dystrophy (DMD), X-linked chronic granulomatous disease (CYBB), X-linked retinitis 
pigmentosa (RPGR), and ornithine transcarbamylase deficiency (OTC). See Genetically Related Disorders, 
Contiguous-gene rearrangements.
Note: Alternatively, next-generation sequencing (NGS), such as exome sequencing or genome sequencing, may 
identify a large deletion involving XK, particularly in a male; however, detection of a deletion by NGS must be 
confirmed by an orthogonal (i.e., statistically independent) method.
Option 2
(Determination of the McLeod blood group phenotype followed by single-gene testing for those in whom 
McLeod blood group phenotyping supports the diagnosis)
Single-gene testing. When the phenotypic and laboratory findings (specifically McLeod blood group 
phenotyping) support the diagnosis of McLeod neuroacanthocytosis syndrome [Frey et al 2015], perform 
sequence analysis of XK to detect small intragenic deletions/insertions and missense, nonsense, and splice site 
variants. If no pathogenic variant is found, perform gene-targeted deletion/duplication analysis to detect 
intragenic deletions or duplications.
Note: (1) Lack of amplification by PCR prior to sequence analysis can suggest a putative (multi)exon or whole-
gene deletion on the X chromosome in affected males; confirmation requires additional testing by gene-targeted 
deletion/duplication analysis. (2) Gene-targeted deletion/duplication testing will detect deletions ranging from a 
single exon to the whole gene; however, breakpoints of large deletions and/or deletion of adjacent genes may not 
be detected in an affected female by these methods and may require CMA (see Option 1).
Option 3
(For symptomatic individuals in whom the diagnosis of McLeod neuroacanthocytosis syndrome has not been 
considered)
When the diagnosis of McLeod neuroacanthocytosis syndrome has not been considered in a symptomatic 
individual, the options are a multigene panel or comprehensive genomic testing.
A multigene panel that includes XK and other genes of interest (see Differential Diagnosis) is most likely to 
identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of 
uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype. Note: (1) 
The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by 
laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with 
the condition discussed in this GeneReview. (3) In some laboratories, panel options may include a custom 
laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the 
clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other 
McLeod Neuroacanthocytosis Syndrome 5
non-sequencing-based tests. For this disorder a multigene panel that also includes deletion/duplication analysis 
is recommended (see Table 1).
For an introduction to multigene panels click here. More detailed information for clinicians ordering genetic 
tests can be found here.
Comprehensive genomic testing involves either exome sequencing or genome sequencing. If exome 
sequencing is not diagnostic, exome array (when clinically available) needs be considered to detect (multi)exon 
deletions or duplications that cannot be detected by exome sequencing.
For an introduction to comprehensive genomic testing click here. More detailed information for clinicians 
ordering genomic testing can be found here.
Table 1. Molecular Genetic Testing Used in McLeod Neuroacanthocytosis Syndrome
Gene 1 Method Proportion of Probands with a Pathogenic Variant 2 Detectable by Method
XK
Sequence analysis 3, 4 ~60% 5, 6
Gene-targeted deletion/duplication analysis 7 ~40% 5, 6, 8
Chromosomal microarray analysis 9 ~30% 6, 8
1. See Table A. Genes and Databases for chromosome locus and protein.
2. See Molecular Genetics for information on allelic variants detected in this gene.
3. Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. 
Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon 
or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click here.
4. Lack of amplification by PCR prior to sequence analysis can suggest a putative (multi)exon or whole-gene deletion on the X 
chromosome in affected males; confirmation requires additional testing by gene-targeted deletion/duplication analysis.
5. Roulis et al [2018]
6. A current list of XK pathogenic variants is maintained here: IBST (scroll down; select Blood Group Allele Terminology, then XK).
7. Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods used may include quantitative 
PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect 
single-exon deletions or duplications. Gene-targeted deletion/duplication testing will detect deletions ranging from a single exon to the 
whole gene; however, breakpoints of large deletions and/or deletion of adjacent genes (see Genetically Related Disorders, Contiguous-
gene rearrangements) may not be detected by these methods.
8. Note that most reported deletions and duplications are large enough to likely be detected by CMA; however, gene-targeted deletion/
duplication analysis does have a higher resolution.
9. Chromosomal microarray analysis (CMA) uses oligonucleotide or SNP arrays to detect genome-wide large deletions/duplications 
(including XK) that cannot be detected by sequence analysis. The ability to determine the size of the deletion/duplication depends on 
the type of microarray used and the density of probes in the Xp21.1 region. CMA designs in current clinical use target the Xp21.1 
region.
Clinical Characteristics
Clinical Description
McLeod neuroacanthocytosis syndrome (MLS) is a multisystem disorder with central nervous system (CNS), 
neuromuscular, and hematologic manifestations in males. CNS manifestations of MLS resemble Huntington 
disease. Symptoms comprise the prototypic triad of a progressive neurodegenerative basal ganglia disease 
including (1) movement disorder, (2) cognitive alterations, and (3) psychiatric symptoms [Danek et al 2001a, 
Jung et al 2007]. It should be noted that each sign and symptom may develop in isolation or in variable 
combinations.
Choreiform movements are the presenting manifestation in about 30% of individuals with MLS, and develop in 
up to 95% of individuals over time [Danek et al 2001b, Jung et al 2001a, Hewer et al 2007]. Some individuals 
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with MLS develop head drops, feeding dystonia, and gait abnormalities, manifestations formerly believed to be 
specific to another type of neuroacanthocytosis, the autosomal recessive chorea-acanthocytosis [Chauveau et al 
2011, Gantenbein et al 2011].
Cognitive alterations are not a major presenting feature of MLS; however, frontal-type cognitive deficits are 
eventually found in at least 50% of individuals during the course of the disease [Danek et al 2001a, Jung et al 
2001a, Danek et al 2004, Hewer et al 2007].
About 20% of individuals initially manifest psychiatric abnormalities including personality disorder, anxiety, 
depression, obsessive-compulsive disorder, bipolar disorder, or schizo-affective disorder. Psychopathology 
develops in about 80% of individuals over time [Danek et al 2001a, Jung et al 2001a, Jung & Haker 2004, 
Walterfang et al 2011].
Seizures are the presenting manifestation in about 20% of individuals. Up to 40% of individuals with MLS 
eventually have seizures, usually described as generalized seizures.
Neuromuscular manifestations are not a common presenting manifestation of MLS. However, almost all 
individuals with MLS have absent deep tendon reflexes as an indication of a (mostly subclinical) sensorimotor 
axonopathy [Danek et al 2001a, Jung et al 2001a]. About 50% of individuals develop clinically relevant muscle 
weakness or atrophy of a neurogenic nature during the disease course. Deterioration rate is slow, and few 
individuals develop severe weakness [Kawakami et al 1999, Danek et al 2001a, Jung et al 2001a, Hewer et al 
2007].
Cardiac manifestations including dilated cardiomyopathy, atrial fibrillation, and tachyarrhythmia are rarely 
presenting signs and symptoms of MLS. About 60% of individuals develop cardiac manifestations over time 
[Witt et al 1992, Danek et al 2001a, Oechslin et al 2009]. In seven males with MLS, one presented with a 
cardiomyopathy and died from sudden cardiac death in the absence of any cardiovascular risk factors. Autopsy 
demonstrated eccentric hypertrophy and mild left ventricular dilatation. Histopathology was not specific and 
revealed focal myocyte hypertrophy, slight variation of myofiber size, and patchy interstitial fibrosis [Witt et al 
1992, Oechslin et al 2009]. Comparable histologic findings were observed in the heart of the only individual with 
MLS who has undergone cardiac transplantation [Laurencin et al 2018].
Hepatosplenomegaly, most probably resulting from compensated hemolysis, occurs in about one third of males 
with MLS [Danek et al 2001a].
About 30% of males with the McLeod blood group phenotype do not have neuromuscular or CNS findings at 
the time of initial diagnosis of the blood group abnormalities and are only recognized during routine workup in 
blood banks or in the course of family evaluations [Danek et al 2001a, Jung et al 2001a, Jung et al 2007]. 
However, most males with the McLeod blood group phenotype developed neurologic manifestations during 
long-term follow up [Danek et al 2001a, Hewer et al 2007].
The age of onset of neurologic manifestations ranges from 18 to 61 years; the majority of individuals become 
symptomatic before age 40 years. Almost all clinical observations indicate a slowly progressive disease course 
[Danek et al 2001a, Jung et al 2001a, Valko et al 2010]. Because of difficulty in determining the exact onset of 
disease, few reliable data regarding disease duration are available. Activities of daily living may become impaired 
as a result of the movement disorder, psychiatric manifestations, intellectual disability, and/or cardiomyopathy.
The interval between reported disease onset and death ranges from seven to 51 years, and the mean age of death 
is 53 years (range: 31 to 69 years) [Danek et al 2001a, Jung et al 2001a, Hewer et al 2007, Walker et al 2019]. 
Mean disease duration from diagnosis to death was 21 years [Walker et al 2019]. Cardiac problems, in particular 
tachyarrhythmia, appear to be a major cause of premature death in MLS; other causes of death included 
pneumonia, seizure, suicide, and sepsis [Walker et al 2019].
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The hematologic manifestations are red blood cell acanthocytosis and compensated hemolysis. Allo-antibodies 
in the Kell and Kx blood group system can cause strong reactions to transfusions of incompatible blood and 
severe anemia in newborns of Kell-negative mothers.
Females
Females who are heterozygous for an XK pathogenic variant have mosaicism for the Kell system blood group 
and RBC acanthocytosis by virtue of X-chromosome inactivation [Øyen et al 1996, Kawakami et al 1999, Jung et 
al 2001a, Singleton et al 2003, Jung et al 2007]. Some heterozygous females may develop clinical manifestations 
such as chorea or late-onset cognitive decline.
The most probable reason for the following clinical manifestations observed in female heterozygotes is skewed 
X-chromosome inactivation, in which the X chromosome with the normal XK allele is by chance inactivated in a 
disproportionately large number of cells [Ho et al 1996]. Pertinent observations are:
• One female heterozygote developed the typical MLS phenotype [Hardie et al 1991].
• A female heterozygote had acanthocytosis, a bimodal pattern of Kell blood group antigens on flow 
cytometry, elevated serum creatine kinase concentrations, and a tic-like movement disorder [Kawakami et 
al 1999].
• In one family, female heterozygotes had slight cognitive deficits and reduced striatal glucose uptake in the 
absence of an obvious movement disorder [Jung et al 2001a].
Other Studies
Serum concentrations of LDH, AST, and ALT may also be elevated [Danek et al 2001a, Jung et al 2001a]. These 
elevated values reflect muscle cell pathology and should not be misinterpreted as hepatic pathology.
Magnetic resonance spectroscopy (MRS). 1H-MRS demonstrates pathologic NAA/(Cr+Cho) ratios in frontal, 
temporal, and insular areas with an individual pattern in males with MLS who have predominant psychiatric or 
neuropsychological manifestations [Dydak et al 2006].
Nuclear medicine. SPECT studies using 123I-IMP and 123I-IBZM revealed reduction of striatal perfusion and 
striatal D2-receptor density, respectively, in some males with MLS [Danek et al 1994, Oechsner et al 2001].
Using [18F]-FDG (2-fluoro-2-deoxy-glucose) PET, bilaterally reduced striatal glucose uptake was found in all 
symptomatic individuals with MLS [Jung et al 2001a, Oechsner et al 2001]. Quantitative FDG-PET also 
demonstrated reduced striatal glucose uptake in asymptomatic males with the McLeod blood group phenotype 
and in female heterozygotes [Jung et al 2001a, Oechsner et al 2001]. The degree of reduction of striatal glucose 
uptake also correlated with disease duration [Jung et al 2001a].
Muscle biopsy shows myopathic as well as neurogenic alterations, which were predominant in most studies:
• Several studies demonstrated fiber type grouping, type 1 fiber predominance, type 2 fiber atrophy, 
increased variability in fiber size, and increased central nucleation [Swash et al 1983, Jung et al 2001b].
• In a series of ten individuals with MLS, including the original index patient, all had abnormal muscle 
histology: four had clear but nonspecific myopathic changes; however, all had neurogenic changes of 
variable degree consistent with predominant neurogenic muscle atrophy [Hewer et al 2007].
• One individual with an XK pathogenic missense variant had normal histologic and immunohistochemical 
findings [Jung et al 2003].
• In muscle of healthy individuals, Kell antigen was located in the sarcoplasmic membranes and Kx 
immunohistochemistry revealed type 2 fiber-specific intracellular staining most probably confined to the 
sarcoplasmic reticulum. Muscle in males with MLS revealed no expression of Kx or Kell [Jung et al 2001b].
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Nerve histology. Nerve biopsy may demonstrate a chronic axonal neuropathy with prominent regenerative 
activity and selective loss of large myelinated fibers [Dotti et al 2004].
Postmortem motor and sensory nerve examinations demonstrated axonal motor neuropathy [Hewer et al 2007].
Brain pathology. Data from four individuals with MLS (3 males and 1 manifesting female heterozygote) are 
available [Hardie et al 1991, Danek et al 2008, Geser et al 2008]:
• In the manifesting female carrier, marked striatal atrophy was noted, corresponding to nonspecific loss of 
nerve cells and reactive astrocytic gliosis with predominant alterations in the head of the caudate nucleus 
[Hardie et al 1991].
• In two males similar alterations were found with severe atrophy of the striatum and (less pronounced) of 
the globus pallidus [Danek et al 2008, Geser et al 2008]. Marked neuronal loss and astrocytic gliosis were 
observed on histologic examination. Moderate focal subcortical and subtle cortical astrocytic gliosis, 
particularly in frontal areas, was noted.
• In contrast to chorea-acanthocytosis (ChAc), none of the four individuals with MLS demonstrated 
pathology in the thalamus or substantia nigra. Neither Lewy bodies nor definite abnormalities in other 
brain areas (e.g., the cortex) were observed.
Genotype-Phenotype Correlations
Data presently available are insufficient to draw conclusions about genotype-phenotype correlations in McLeod 
neuroacanthocytosis syndrome [Danek et al 2001a]. MLS shows considerable phenotypic variability, even 
between family members with identical XK variants [Danek et al 2001b, Walker et al 2007a].
Only three pathogenic XK missense variants have a possible genotype-phenotype correlation. Although rare, 
they are potentially useful in the elucidation of structural and functional relationships. For more details, see 
Table 6.
• The c.979G>A variant was associated with an isolated immunohematologic phenotype without evidence 
for muscular, central, and peripheral nervous system involvement [Jung et al 2003].
• An individual with the c.664C>G variant did not show significant neurologic or systemic abnormalities 
[Walker et al 2007b].
• A single-base substitution in an intron near a splice junction (c.508+5G>A, resulting in alternative 
splicing and some degree of normal splicing) did not lead to any significant neurologic abnormalities 
[Walker et al 2007b].
Penetrance
In males, the penetrance of neurologic and neuromuscular manifestations of MLS is high – perhaps even 
complete – after age 50 years. Available data indicate that most males with the McLeod blood group phenotype 
will develop clinical manifestations of McLeod neuroacanthocytosis syndrome [Bertelson et al 1988, Hardie et al 
1991, Danek et al 2001a, Jung et al 2001b]. In a few individuals, however, neurologic and neuromuscular 
manifestations may be absent or only minor even after long-term follow up [Jung et al 2003, Walker et al 2007b].
In the past, many reports (including that of the index case) described only hematologic findings, and no 
neurologic or neuroimaging workup was performed in these individuals [Allen et al 1961, Symmans et al 1979, 
Bertelson et al 1988, Lee et al 2000]. However, in many of these individuals neurologic manifestations were 
identified during long-term follow up [Bertelson et al 1988, Danek et al 2001a].
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Nomenclature
The term "neuroacanthocytosis" refers to several genetically and phenotypically distinct disorders [Danek et al 
2004, Danek et al 2005]; see Differential Diagnosis.
The term "McLeod blood group phenotype" (named after the first proband, Hugh McLeod) describes the 
immunohematologic abnormalities consisting of absent expression of Kx RBC antigen and reduced expression 
of Kell RBC antigens in the index case originally described by Allen et al [1961].
The terms "Kell blood group precursor" and "Kell blood group precursor substance" for the XK protein or the Kx 
RBC antigen, respectively, are incorrect and no longer in use.
Prevalence
The prevalence of MLS cannot be determined based on the data available from the approximately 250 cases 
known worldwide. The prevalence is estimated at 1:10,000,000 [Walker et al 2019].
Genetically Related (Allelic) Disorders
No other phenotypes are known to be caused by pathogenic variants in XK alone.
Contiguous-gene rearrangements. Other genes that lie in close proximity to XK at Xp21.1 and the disorders 
caused by their deletion include the following [Peng et al 2007]:
• 5' of XK on Xp21.1: DMD (Duchenne muscular dystrophy)
• 3' of XK on Xp21.1:
⚬ CYBB (X-linked chronic granulomatous disease)
⚬ RPGR (RPGR-related retinitis pigmentosa)
⚬ OTC (ornithine transcarbamylase deficiency)
Note: Concurrent deletion of CYBB and XK is the most common; deletion of all five genes is exceedingly rare.
Differential Diagnosis
Table 2. Other Genes of Interest in the Differential Diagnosis of McLeod Neuroacanthocytosis Syndrome (MLS)
Gene Disorder MOI
Clinical Features of Differential Diagnosis Disorder
Overlapping w/MLS Distinguishing from MLS
HTT Huntington disease(HD) AD
• May appear indistinguishable 
from MLS
• Progressive choreatic 
movement disorder
• Cognitive & psychiatric 
disturbances
• Anticipation
• Absence of seizures, 
myopathy, & 
cardiomyopathy
Neuroacanthocytosis syndromes 1 assoc w/lipid malabsorption primarily affecting spinal cord, cerebellum, & PNS 2
ANGPTL3 Hypobetalipoproteinemia type 2(OMIM 605019) 2 AR • Acanthocytosis
• Dysarthria
• Neuropathy
• Areflexia
• Pigmentary retinopathy
• Absence of basal ganglia 
involvement
APOB Hypobetalipoproteinemia type 1(OMIM 615558) 2 AR
MTTP Abetalipoproteinemia(Bassen-Kornzweig disease) 2 AR
Neuroacanthocytosis syndromes predominantly affecting CNS (esp basal ganglia) 3
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Table 2. continued from previous page.
Gene Disorder MOI
Clinical Features of Differential Diagnosis Disorder
Overlapping w/MLS Distinguishing from MLS
JPH3 HDL2 AD
• Progressive course
• Dystonia
• Presentation w/chorea or 
parkinsonism may change w/
evolution of the disease
• Almost all affected 
individuals reported to date 
have been of African 
ancestry
• RBC acanthocytes not 
substantiated 5
PANK2
PKAN; including HARP 4
(see also Neurodegeneration with 
Brain Iron Accumulation Disorders 
Overview)
AR
• Progressive dystonia
• Dysarthria
• Rigidity
• In ~25% of individuals: 
"atypical" presentation w/
onset age >10 yrs, prominent 
speech defects, psychiatric 
disturbance, & more gradual 
disease progression
• In ≥8%: acanthocytosis
• Usually childhood or 
adolescent onset
• Basal ganglia iron deposition
• "Eye of the tiger" sign on 
MRI characteristic
• Pigmentary retinopathy
PRNP HDL1(OMIM 603218) AD
Phenotype may be indistinguishable 
from HD.
• Rapidly progressive course
• No hematologic, 
neuromuscular, or cardiac 
manifestations
VPS13A Chorea-acanthocytosis(ChAc) AR
• Progressive movement 
disorder (primarily chorea)
• Subclinical myopathy → 
progressive distal muscle 
wasting & weakness
• Mental changes
• Seizures
• Progressive cognitive & 
behavioral changes that 
resemble a frontal lobe 
syndrome
• Dystonia affecting trunk & esp 
oral region & tongue → 
dysarthria & serious 
dysphagia w/resultant weight 
loss
• May present w/a 
parkinsonian syndrome
• Habitual tongue & lip biting 
characteristic
Other disorders
ATN1 DRPLA AD
ATP7B Wilson disease AR
ATXN3 SCA3 AD
CP Aceruloplasminemia AR
Aceruloplasminemia could be 
considered a neurodegeneration w/
brain iron accumulation. 6
DYT3 X-linked dystonia-parkinsonism(DYT3, DYT-TAF1, Lubag) XL
FTL Neuroferritinopathy AD
HPRT1 Lesch-Nyhan syndrome XL
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Table 2. continued from previous page.
Gene Disorder MOI
Clinical Features of Differential Diagnosis Disorder
Overlapping w/MLS Distinguishing from MLS
NKX2-1 Benign hereditary chorea(see NKX2-1-Related Disorders) AD
PLA2G6
PLA2G6-associated 
neurodegeneration
(infantile neuroaxonal dystrophy; 
Karak syndrome)
AR
TBP SCA17 AD
AD = autosomal dominant; AR = autosomal recessive; CNS = central nervous system; DRPLA = dentatorubral-pallidoluysian atrophy; 
HDL = Huntington disease-like; MOI = mode of inheritance; PKAN = pantothenate kinase-associated neurodegeneration; PNS = 
peripheral nervous system; SCA = spinocerebellar ataxia; XL = X-linked
1. Neurologic disorders associated with RBC acanthocytosis have been summarized as neuroacanthocytosis syndromes [Danek et al 
2004, Danek et al 2005, Jung et al 2011].
2. Neurologic findings include: 
a. A progressive spinocerebellar degeneration with gait ataxia, dysmetria, and dysarthria; 
b. A demyelinating sensorimotor and axonal peripheral neuropathy with hyporeflexia and diminished vibration and position sense;
c. Rarely, pyramidal tract signs; and 
d. Rarely, cranial nerve involvement [Kane & Havel 1995, Tarugi & Averna 2011].
3. Results in a chorea syndrome resembling Huntington disease
4. HARP syndrome (hypoprebetalipoproteinemia, acanthocytosis, retinitis pigmentosa, and pallidal degeneration) is allelic with PKAN 
[Ching et al 2002, Houlden et al 2003]. The continued use of this term is discouraged particularly since "hypoprebetalipoproteinemia" 
is not a meaningful entity.
5. Anderson et al [2017]
6. Kassubek et al [2017]
Management
Evaluations Following Initial Diagnosis
To establish the extent of disease in an individual diagnosed with McLeod neuroacanthocytosis syndrome 
(MLS), the evaluations summarized in Table 3 (if not performed as part of the evaluation that led to the 
diagnosis) are recommended.
Table 3. Recommended Evaluations Following Initial Diagnosis in Individuals with McLeod Neuroacanthocytosis Syndrome
System/Concern Evaluation Comment
Neurologic
For movement disorder
Choreiform movements; head drops; apply unified 
Huntington Disease Rating Scale (UHDRS) & perform brain 
MRI
For seizures Usually generalized seizures; perform EEG 1
For neuromuscular involvement Absent DTRs, muscle weakness or atrophy; determine serum CK, ALT, AST, & LDH levels; EMG & NCV studies
Cognitive To include motor, speech/language evaluation, & general cognitive skills
Frontotemporal & executive deficits; perform formal 
neuropsychological evaluation &/or Montreal cognitive 
assessment
Psychiatric
For frontal-type deficits; personality disorder, 
anxiety, depression, obsessive-compulsive disorder, 
bipolar disorder, schizo-affective disorder
Perform standardized psychiatric assessment; evaluation of 
symptom-oriented psychotherapeutic & 
psychopharmacologic interventions. Contact w/a patient 
advocacy organization may provide additional benefit. 2
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Table 3. continued from previous page.
System/Concern Evaluation Comment
Feeding Feeding/nutritional assessment Feeding dystonia; consider clinical &/or fiberoptic feeding evaluation
Cardiac Dilated cardiomyopathy, atrial fibrillation, tachyarrhythmia
Usually develop over time 1; perform echocardiography 
&Holter-ECG
Hematologic
Immunohematologic evaluation: erythrocyte 
phenotyping for Kell & Kx antigens; expression of 
Kell protein by flow cytometry, search for anti-
public alloantibodies, direct antiglobulin test 3
↑ risk of transfusion reactions w/repetitive blood 
transfusions; consider autologous blood banking when 
planned surgery may require blood transfusions.
Miscellaneous/
Other
Consultation w/clinical geneticist &/or genetic 
counselor
DTRs = deep tendon reflexes; EEG= electroencephalogram
1. Early recognition and treatment of cardiac manifestations and seizures are important, as these potential complications may be severe 
and could cause premature death [Danek et al 2001a, Hewer et al 2007, Walker et al 2019].
2. Irvine & Irvine [2013]
3. Frey et al [2015]
Treatment of Manifestations
Table 4. Treatment of Manifestations in Individuals with McLeod Neuroacanthocytosis Syndrome
Manifestation/
Concern Treatment Considerations/Other
Chorea
• Dopamine antagonists incl tiapride, 
clozapine, or quetiapine
• Dopamine depletor: tetrabenazine
Avoid use of typical neuroleptics (e.g., 
haloperidol) because of risk of extrapyramidal 
adverse events.
Seizures Antiepileptic drugs 1
Avoid long-term use of benzodiazepines because 
of possible negative effect on neuromuscular 
system.
Neuromuscular
• Physiotherapy
• Sufficient supplementation of calories & 
protein
• Supplementation of vitamins D & B12 if 
needed
• Endurance exercise as tolerated may be 
helpful.
• Avoid strength exercises, in particular of 
the eccentric type.
Cognitive Cognitive training is probably rarely indicated.
Consider counseling as needed based on daily 
living &/or work-related requirements, incl job 
alternatives.
Psychiatric Standard treatment according to manifestation
Extended & continuous multidisciplinary 
psychosocial support for affected individuals & 
families
Cardiac Standard treatment according to clinical &/or ECG presentation
Hematologic Avoid transfusion of Kx+ homologous blood products.
Avoid repetitive blood transfusions; Consider 
cryopreservation of Kx- autologous blood for 
future use.
1. When epilepsy is suspected, EEG should be performed and AED treatment considered (based on standard guidelines including the 
monitoring of medication-specific laboratory parameters and serum concentrations). Because of the increased risk of rhabdomyolysis, 
treatment with neuroleptics – in particular clozapine – should be carefully monitored, both clinically and with serum CK 
measurements.
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Surveillance
Table 5. Recommended Surveillance for Individuals with McLeod Neuroacanthocytosis Syndrome
System/Concern Evaluation Frequency
Cardiac Cardiac examinations (Holter ECG & echocardiography)
Initially every 2-3 yrs; more frequently if abnormal clinical findings 
&/or cardiac examinations
Seizures EEG Whenever new-onset seizures are suspected
Muscle
(rhabdomyolysis) Serum CK concentration Regularly, in particular when under neuroleptic treatment
Agents/Circumstances to Avoid
Blood transfusions with Kx antigens should be avoided in males with the McLeod blood group phenotype. Kx-
negative blood or, if possible, banked autologous blood should be used for transfusions. Note that because 
heterozygous females have both Kx+ and Kx- red blood cells, they can be transfused with Kx+ homologous 
blood products.
Evaluation of Relatives at Risk
It is appropriate to clarify the genetic status of apparently asymptomatic at-risk relatives of any age in order to 
identify as early as possible those who would benefit from: (1) detailed blood compatibility information to 
prevent transfusion of Kx+ homologous blood products, and (2) possible prophylactic cryopreservation of 
autologous blood for use in future transfusions.
See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.
Pregnancy Management
In female heterozygotes, the probability of manifestations of the McLeod neuroacanthocytosis syndrome in the 
reproductive period is presumably very low; thus, no particular recommendations can be made.
Therapies Under Investigation
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for information on clinical studies 
for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Genetic Counseling
Genetic counseling is the process of providing individuals and families with information on the nature, inheritance, 
and implications of genetic disorders to help them make informed medical and personal decisions. The following 
section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for 
family members. This section is not meant to address all personal, cultural, or ethical issues that individuals may 
face or to substitute for consultation with a genetics professional. —ED.
Mode of Inheritance
McLeod neuroacanthocytosis syndrome (MLS) is inherited in an X-linked manner.
Risk to Family Members
Parents of a male proband
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• The father of an affected male will not have the disease nor will he be hemizygous for the XK pathogenic 
variant; therefore, he does not require further evaluation/testing.
• In a family with more than one affected individual, the mother of an affected male is an obligate 
heterozygote.
• If a male is the only affected family member (i.e., a simplex case), the mother may be a heterozygote or the 
affected male may have a de novoXK pathogenic variant, in which case the mother is not a carrier. One de 
novoXK pathogenic variant has been described in MLS [Supple et al 2001].
• If a woman has more than one affected son and the XK pathogenic variant cannot be detected in her 
leukocyte DNA, she may have germline mosaicism. No data regarding germline mosaicism in MLS are 
available to date.
Sibs of a male proband. The risk to sibs depends on the genetic status of the mother:
• If the mother of the proband has a pathogenic variant, the chance of transmitting it in each pregnancy is 
50%. Males who inherit the variant will be affected; females who inherit the variant will be heterozygotes 
and will usually not be affected. Significant interfamilial phenotypic variability has been observed in MLS 
(see Clinical Description).
Females heterozygous for XK pathogenic variants have mosaicism for the Kell and Kx blood group 
antigens but usually lack CNS and neuromuscular manifestations. However, some heterozygous females 
may develop clinical manifestations including chorea or late-onset cognitive decline.
• If the proband represents a simplex case (i.e., a single occurrence in a family) and if the pathogenic variant 
cannot be detected in the leukocyte DNA of the mother, the risk to sibs is low but greater than that of the 
general population because of the theoretic possibility of maternal germline mosaicism.
Offspring of a male proband. Affected males transmit the XK pathogenic variant to:
• All of their daughters who will be heterozygotes and usually will not be affected (see Clinical 
Characteristics, Females);
• None of their sons.
Other family members. A male proband's maternal aunts may be at risk of being heterozygotes and the aunt's 
offspring, depending on their gender, may be at risk of being heterozygotes or of being affected.
Heterozygote (Carrier) Detection
Identification of female heterozygotes requires either (a) prior identification of the XK pathogenic variant in the 
family or, (b) if an affected male is not available for testing, either molecular genetic testing first by sequence 
analysis, and if no XK pathogenic variant is identified, by gene-targeted deletion/duplication analysis or flow 
cytometric analysis of Kx and Kell erythrocyte antigens.
Note: Heterozygous females may very rarely develop clinical manifestations such as chorea or late-onset 
cognitive decline [Sveinsson et al 2018].
Related Genetic Counseling Issues
See Management, Evaluation of Relatives at Risk for information on evaluating at-risk relatives for the purpose 
of early identification of those who would benefit from detailed blood compatibility information to prevent 
transfusion of Kx+ homologous blood products.
Considerations in families with an apparent de novo pathogenic variant. When the mother of a male proband 
with an X-linked condition does not have the pathogenic variant identified in the proband, the pathogenic 
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variant is likely de novo. However, non-medical explanations including alternate maternity (e.g., with assisted 
reproduction) and undisclosed adoption could also be explored.
Family planning
• The optimal time for determination of genetic risk, clarification of genetic status, and discussion of the 
availability of prenatal testing is before pregnancy.
• It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and 
reproductive options) to young adults who are affected, are heterozygotes, or are at risk of being 
heterozygotes.
DNA banking is the storage of DNA (typically extracted from white blood cells) for possible future use. Because 
it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in 
the future, consideration should be given to banking DNA of affected individuals.
Prenatal Testing and Preimplantation Genetic Diagnosis
Once the XK pathogenic variant has been identified in an affected family member, prenatal testing for a 
pregnancy at increased risk and preimplantation genetic diagnosis for MLS are possible.
Differences in perspective may exist among medical professionals and within families regarding the use of 
prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather 
than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of 
the parents, discussion of these issues is appropriate.
Resources
GeneReviews staff has selected the following disease-specific and/or umbrella support organizations and/or registries 
for the benefit of individuals with this disorder and their families. GeneReviews is not responsible for the 
information provided by other organizations. For information on selection criteria, click here.
• Advocacy for Neuroacanthocytosis Patients
39 Coleherne Court
London SW5 0DN
United Kingdom
Phone: 44 (0) 20 7460-8874
Email: ginger@naadvocacy.org; Jen@naadvocacy.org
www.naadvocacy.org
• Cardiomyopathy UK
Chiltern Court
Asheridge Road
Unit 10
Chesham Buckinghamshire HP5 2PX
United Kingdom
Phone: 0800 018 1024 (UK only); 0800 018 1024 (UK only)
Email: info@cardiomyopathy.org
www.cardiomyopathy.org
• European Huntington's Disease Network (EHDN)
Germany
www.ehdn.org
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• Huntington's Disease Society of America (HDSA)
www.hdsa.org
• Neuroacanthocytosis Database (Registry)
Prof. Adrian Danek
Neurologische Klinik
POB 701260
Germany
Phone: 49 (89) 4400-76676
Email: adrian.danek@med.uni-muenchen.de
www.euro-hd.net/html/na/registry
Molecular Genetics
Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables 
may contain more recent information. —ED.
Table A. McLeod Neuroacanthocytosis Syndrome: Genes and Databases
Gene Chromosome Locus Protein Locus-Specific 
Databases
HGMD ClinVar
XK Xp21.1 Membrane transport 
protein XK
XK @ LOVD XK XK
Data are compiled from the following standard references: gene from HGNC; chromosome locus from OMIM; protein from UniProt. 
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click here.
Table B. OMIM Entries for McLeod Neuroacanthocytosis Syndrome (View All in OMIM)
300842 MCLEOD SYNDROME; MCLDS
314850 KELL BLOOD GROUP PROTEIN, MCLEOD SYNDROME-ASSOCIATED; XK
Molecular Pathogenesis
XK encodes XK, a red blood cell antigen. The XK protein has ten transmembrane domains and the structural 
characteristics of a membrane transport protein [Ho et al 1994]. The XK protein attaches to the Kell 
glycoprotein, encoded by KEL on chromosome 7, by a single disulfide bond (XK p.Cys347- Kell p.Cys72) when 
they are coexpressed [Russo et al 1998]. In the red cell membrane, the heterodimeric protein-complex XK-KEL 
is part of the larger membrane multiprotein complex subunit 4.1 (MMPC4.1) containing Band3 glycoprotein, 
glycophorin C, Rh protein, Rh associated glycoprotein, and Duffy protein, which supports red cell cytoskeleton 
stability [Frey et al 2015, Lux 2016]. XK may also be important for transmembrane exchange of divalent cations 
(Ca++, Mg++) and Gardos channel function [De Franceschi et al 2005, Rivera et al 2013].
XK and Kell are predominantly coexpressed in erythroid tissues, but their expression in non-erythroid tissues 
differs. XK is ubiquitously expressed in many other tissues, especially in high amounts in skeletal muscle and 
brain [Russo et al 2000, Camara-Clayette et al 2001, Jung et al 2001b]; however, Kell is not present in brain and 
skeletal muscle in that species. XK is expressed in various cerebral regions, with high amounts in pontine region, 
olfactory lobe, and cerebellum [Lee et al 2007]. It has been proposed that the function of isolated XK in non-
erythroid tissue differs from that of XK in combination with Kell.
Mechanism of disease causation. McLeod neuroacanthocytosis syndrome occurs through a loss-of-function 
mechanism.
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XK-specific laboratory technical considerations. A naming convention for abnormal XK alleles has been 
established by the International Society of Blood Transfusion (IBST; scroll down and select Blood Group Allele 
Tables, then XK). The XK protein reference allele is defined as XK*01. Alleles associated with MLS are defined 
as XK*N.# beginning with 01, with N indicating null and # being assigned to each reported abnormal allele (e.g., 
c.664C>G [p.Arg222Gly] is designated XK*N.27).
Note: Stepwise partitioning of Xp21 has been used as an alternative method to define the exact breakpoints of 
contiguous-gene deletions [Gassner et al 2017, Sveinsson et al 2018].
Notable XK variants. All three of the reported pathogenic missense variants occurred in the transmembrane 
domains and on highly conserved amino-acid residues that are evolutionarily related to XK, suggesting possible 
important roles in structure or function. The p.Glu327 and p.Arg222 residues may be involved in the basic 
structure of XK rather than in its function; the p.Cys294 residue, which is conserved specifically in the XK 
family, may be critical for normal function [Walker et al 2007b].
Table 6. Notable XK Pathogenic Variants
Reference Sequences DNA Nucleotide Change Predicted Protein Change(Alias 1) Comment [Reference]
NM_021083.2
NP_066569.1
c.664C>G p.Arg222Gly(XK*N.27)
The 3 reported XK missense variants are predicted to 
disrupt either structure or function [Walker et al 2007b].c.880T>C
p.Cys294Arg
(XK*N.28)
c.979G>A p.Glu327Lys(XK*N.29)
Variants listed in the table have been provided by the authors. GeneReviews staff have not independently verified the classification of 
variants.
GeneReviews follows the standard naming conventions of the Human Genome Variation Society (varnomen.hgvs.org). See Quick 
Reference for an explanation of nomenclature.
1. Variant designation that does not conform to current naming conventions
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